SCHEMBL7922797

SCHEMBL7922797

COc1cc(F)ccc1C=[N+]([O-])C(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
KCNH2 Q12809 1/20 0.39
NFE2L2 Q16236 3/20 0.35
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35
CYP1A1 P04798 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP1B1 Q16678 2/20 0.35
AR P10275 1/20 0.35
MDM2 Q00987 1/20 0.34
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
FBP1 P09467 1/20 0.33
ALDH1A1 P00352 1/20 0.33
PDGFRB P09619 1/20 0.33
PDGFRA P16234 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6153742 0.80 NFE2L2 (0.44) NFE2L2CYP1A1CYP1A2CYP1B1AR
SCHEMBL7923573 0.80 NFE2L2 (0.42) HTR2AHTR2CKCNH2NFE2L2CYP1A1
SCHEMBL7921446 0.78 ALDH1A1 (0.36) HTR2AHTR2CKCNH2ALDH1A1
SCHEMBL7922778 0.77 NFE2L2 (0.42) NFE2L2FBP1ALDH1A1
SCHEMBL7920975 0.76 ALDH1A1 (0.43) KCNH2ARALDH1A1
SCHEMBL7921534 0.75 CYP1A1 (0.49) NFE2L2CYP1A1CYP1A2CYP1B1ALDH1A1
SCHEMBL34462751 0.72 PRMT1 (0.57) HTR2AHTR2CKCNH2CTSLCTSB
SCHEMBL8441698 0.72 NFE2L2 (0.35) HTR2AHTR2CKCNH2NFE2L2FBP1
SCHEMBL30977631 0.71 ALDH1A1 (0.43) HTR2AHTR2CKCNH2NFE2L2CTSL
SCHEMBL21352189 0.71 CYP1A1 (0.42) HTR2AHTR2CKCNH2NFE2L2CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6194461-B1 USEFUL AS MEDICAMENT FOR TREATING RETINAL DEGENERATIVE DISORDERS; ALPHA-(2,4-DIFLUOROPHENYL)-N-T-BUTYLNITRONE, AND CORRESPONDING AMINES WHICH WOULD BE CONVERTED IN VIVO TO THE NITRONE, FOR EXAMPLE SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-02-27 US disclosed
EP-0945426-A1 NITRONE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1999-09-29 EP disclosed